MX365418B - Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias. - Google Patents
Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.Info
- Publication number
- MX365418B MX365418B MX2014015665A MX2014015665A MX365418B MX 365418 B MX365418 B MX 365418B MX 2014015665 A MX2014015665 A MX 2014015665A MX 2014015665 A MX2014015665 A MX 2014015665A MX 365418 B MX365418 B MX 365418B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- selection
- immune response
- yeast
- response generating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 5
- 238000009169 immunotherapy Methods 0.000 abstract 3
- 238000011319 anticancer therapy Methods 0.000 abstract 2
- 238000001228 spectrum Methods 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 230000003595 spectral effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0036—Step by step routines describing the handling of the data generated during a measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
Abstract
La presente invención se refiere a un método y sistema para predecir por adelantado del tratamiento, si es probable o si no es probables que un paciente con cáncer obtenga beneficio de la administración de una terapia generadora de respuesta inmunitaria a base de levadura, que puede ser inmunoterapia a base de levadura para cáncer positivo a Ras mutada, sola o en combinación con otra terapia anti-cáncer. El método usa espectrometría de masas de una muestra del paciente extraída de sangre y una computadora configurada como un clasificador que usa un conjunto de entrenamiento de espectros marcados por clase de otros pacientes con cáncer ya sea beneficiados o no beneficiados de una terapia generadora de respuesta inmunitaria sola o en combinación con otra terapia anti-cáncer. También se describen métodos de tratamiento de un paciente con cáncer, que comprende administrar una terapia generadora de respuesta inmunitaria a base de levadura, que puede ser inmunoterapia a base de levadura para cáncer positivo a Ras mutada, a un paciente seleccionado por una prueba de acuerdo a los métodos predictivos de espectros de masa, descritos en la presente, en la cual la marca de clase para los espectros indica si es probable que el paciente se beneficie de la inmunoterapia a base de levadura.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664329P | 2012-06-26 | 2012-06-26 | |
US201261664308P | 2012-06-26 | 2012-06-26 | |
PCT/US2013/032024 WO2014003853A1 (en) | 2012-06-26 | 2013-03-15 | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014015665A MX2014015665A (es) | 2015-06-17 |
MX365418B true MX365418B (es) | 2019-06-03 |
Family
ID=48045749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015665A MX365418B (es) | 2012-06-26 | 2013-03-15 | Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9653272B2 (es) |
EP (1) | EP2864792A1 (es) |
JP (1) | JP6355630B2 (es) |
KR (1) | KR102103319B1 (es) |
CN (1) | CN104685360B (es) |
AU (1) | AU2013281221B2 (es) |
CA (1) | CA2878044C (es) |
HK (1) | HK1209835A1 (es) |
IL (1) | IL236266A0 (es) |
MX (1) | MX365418B (es) |
SG (1) | SG11201408652SA (es) |
TW (1) | TWI639001B (es) |
WO (1) | WO2014003853A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6355630B2 (ja) | 2012-06-26 | 2018-07-11 | バイオデシックス・インコーポレイテッドBiodesix Inc | 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法 |
US11594403B1 (en) | 2014-12-03 | 2023-02-28 | Biodesix Inc. | Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample |
TW201621315A (zh) | 2014-12-03 | 2016-06-16 | 拜歐迪希克斯公司 | 使用maldi-tof質譜分析以早期偵測高風險群中之肝細胞癌 |
US11352642B2 (en) | 2015-01-09 | 2022-06-07 | Etubics Corporation | Methods and compositions for combination immunotherapy |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
WO2016175990A1 (en) * | 2015-04-30 | 2016-11-03 | Biodesix, Inc. | Bagged filtering method for selection and deselection of features for classification |
JP6819012B2 (ja) | 2015-06-03 | 2021-01-27 | モンテフィオーレ メディカル センターMontefiore Medical Center | 癌と転移を処置するための低密度焦点式超音波 |
EP3322987B1 (en) * | 2015-07-13 | 2021-09-08 | Biodesix, Inc. | Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
EP3405896A4 (en) * | 2016-01-22 | 2019-09-25 | Otraces Inc. | SYSTEMS AND METHODS FOR ENHANCING DIAGNOSIS OF DISEASE |
US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
US11232940B2 (en) * | 2016-08-02 | 2022-01-25 | Virgin Instruments Corporation | Method and apparatus for surgical monitoring using MALDI-TOF mass spectrometry |
WO2018129301A1 (en) * | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
CN111836666A (zh) * | 2017-11-09 | 2020-10-27 | 蒙特非奥里医疗中心 | 用于治疗癌症和转移的低能量免疫致敏 |
US20210369775A1 (en) | 2017-12-15 | 2021-12-02 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
CN112105381A (zh) * | 2018-03-29 | 2020-12-18 | 佰欧迪塞克斯公司 | 用于识别癌症患者的原发性免疫抗性的设备和方法 |
EP3924974A4 (en) * | 2019-02-15 | 2022-11-16 | Biodesix, Inc. | PREDICTIVE TEST TO IDENTIFY EARLY-STAGE NSCLC PATIENTS WITH HIGH RISK OF RECURRENCE POST-SURGERY |
CN110674947B (zh) * | 2019-09-02 | 2021-02-19 | 三峡大学 | 基于Stacking集成框架的光谱特征变量选择与优化方法 |
CN112164448B (zh) * | 2020-09-25 | 2021-06-22 | 上海市胸科医院 | 免疫治疗疗效预测模型训练方法、预测***及方法和介质 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
JPS61219387A (ja) | 1985-03-27 | 1986-09-29 | Suntory Ltd | 新規な酵母プラスミドおよびその形質転換体 |
US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
WO1995004542A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Cloning and characterization of the complete mage-1 gene |
US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
US20070048860A1 (en) | 1997-10-10 | 2007-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Carcinoembryonic antigen (CEA) peptides |
US20010055589A1 (en) | 1998-06-17 | 2001-12-27 | University Of Connecticut | Cancer immunotherapy improved by prior radiotherapy |
US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
ATE319475T1 (de) | 2000-04-06 | 2006-03-15 | Seer Pharmaceuticals Llc | Microbielles wirkstoffabgabesystem |
AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
AU2002252456A1 (en) | 2001-03-23 | 2002-10-08 | Aphton Corporation | Combination treatment of pancreatic cancer |
US7465454B2 (en) | 2002-12-16 | 2008-12-16 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
KR101158709B1 (ko) | 2004-09-06 | 2012-06-22 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 오디오 신호 강화 |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
US8013927B2 (en) | 2005-07-08 | 2011-09-06 | Nikon Corporation | Solid-state image sensors |
KR20080043775A (ko) | 2005-07-11 | 2008-05-19 | 글로브이뮨 | 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물 |
US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
US7736642B2 (en) | 2006-02-02 | 2010-06-15 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
US7867775B2 (en) | 2006-03-31 | 2011-01-11 | Biodesix, Inc. | Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway |
US7906342B2 (en) | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
US8024282B2 (en) | 2006-03-31 | 2011-09-20 | Biodesix, Inc. | Method for reliable classification of samples in clinical diagnostics using an improved method of classification |
US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
US7858389B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway |
US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
WO2008085024A1 (en) * | 2007-01-12 | 2008-07-17 | Erasmus University Medical Center Rotterdam | Identification and detection of peptides relating to specific disorders |
SG171577A1 (en) | 2007-02-02 | 2011-06-29 | Globeimmune Inc | Methods for producing yeast-based vaccines |
CN101730542A (zh) | 2007-03-19 | 2010-06-09 | 环球免疫公司 | 用于靶向消除癌症靶向疗法的突变逃逸的组合物和方法 |
CA2727559A1 (en) | 2008-06-11 | 2009-12-17 | Nils Aage Brunner | Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment |
JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
WO2010080804A1 (en) | 2009-01-06 | 2010-07-15 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
JP5759980B2 (ja) | 2009-04-17 | 2015-08-05 | グローブイミューン,インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
JP2011001315A (ja) | 2009-06-19 | 2011-01-06 | Cellex Corp | 膵臓癌の免疫療法剤 |
CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
EP2539704A4 (en) | 2010-02-24 | 2015-12-02 | Biodesix Inc | CANCER PATIENT SELECTION FOR ADMINISTRATION OF THERAPEUTIC AGENTS USING MASS SPECTROMETRY ANALYSIS |
EP2547792A4 (en) | 2010-03-14 | 2013-11-27 | Globeimmune Inc | PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY |
WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
KR20140007409A (ko) | 2011-01-28 | 2014-01-17 | 바이오디식스, 인크. | 호르몬 및 병용 요법을 위해 전이성 유방암 환자를 선택하기 위한 예측 시험 |
PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
RU2619850C2 (ru) | 2011-03-17 | 2017-05-18 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей с brachyury |
CN103732250A (zh) | 2011-06-14 | 2014-04-16 | 全球免疫股份有限公司 | 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法 |
SG10201607663YA (en) | 2011-08-17 | 2016-11-29 | Globeimmune Inc | Yeast-muc1 immunotherapeutic compositions and uses thereof |
CA2856981A1 (en) | 2011-11-23 | 2013-06-27 | Uti Limited Partnership | Expression signature for staging and prognosis of prostate, breast and leukemia cancers |
US20150079078A1 (en) | 2012-04-13 | 2015-03-19 | Erasmus University Medical Center Rotterdam | Biomarkers for triple negative breast cancer |
US9279798B2 (en) * | 2012-05-29 | 2016-03-08 | Biodesix, Inc. | Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof |
JP6355630B2 (ja) | 2012-06-26 | 2018-07-11 | バイオデシックス・インコーポレイテッドBiodesix Inc | 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法 |
CH715107B1 (fr) | 2018-06-18 | 2021-12-30 | Montres Breguet Sa | Mécanisme de réglage pour mécanisme d'affichage d'horlogerie à rouleau. |
-
2013
- 2013-03-15 JP JP2015520167A patent/JP6355630B2/ja active Active
- 2013-03-15 US US13/835,909 patent/US9653272B2/en active Active
- 2013-03-15 SG SG11201408652SA patent/SG11201408652SA/en unknown
- 2013-03-15 CA CA2878044A patent/CA2878044C/en active Active
- 2013-03-15 WO PCT/US2013/032024 patent/WO2014003853A1/en active Application Filing
- 2013-03-15 KR KR1020157001998A patent/KR102103319B1/ko active IP Right Grant
- 2013-03-15 AU AU2013281221A patent/AU2013281221B2/en active Active
- 2013-03-15 CN CN201380043182.4A patent/CN104685360B/zh active Active
- 2013-03-15 EP EP13714124.8A patent/EP2864792A1/en not_active Withdrawn
- 2013-03-15 MX MX2014015665A patent/MX365418B/es active IP Right Grant
- 2013-05-03 TW TW102115975A patent/TWI639001B/zh active
-
2014
- 2014-12-15 IL IL236266A patent/IL236266A0/en unknown
-
2015
- 2015-10-26 HK HK15110515.8A patent/HK1209835A1/xx unknown
-
2017
- 2017-05-02 US US15/584,275 patent/US10593529B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013281221B2 (en) | 2018-05-17 |
US20170271136A1 (en) | 2017-09-21 |
CN104685360B (zh) | 2018-02-13 |
WO2014003853A1 (en) | 2014-01-03 |
CA2878044C (en) | 2021-10-26 |
KR102103319B1 (ko) | 2020-04-22 |
US9653272B2 (en) | 2017-05-16 |
JP2015528110A (ja) | 2015-09-24 |
HK1209835A1 (en) | 2016-04-08 |
US20130344111A1 (en) | 2013-12-26 |
CN104685360A (zh) | 2015-06-03 |
JP6355630B2 (ja) | 2018-07-11 |
AU2013281221A1 (en) | 2015-02-12 |
TWI639001B (zh) | 2018-10-21 |
CA2878044A1 (en) | 2014-01-03 |
IL236266A0 (en) | 2015-02-26 |
TW201400812A (zh) | 2014-01-01 |
MX2014015665A (es) | 2015-06-17 |
EP2864792A1 (en) | 2015-04-29 |
SG11201408652SA (en) | 2015-01-29 |
KR20150023881A (ko) | 2015-03-05 |
US10593529B2 (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2878044C (en) | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
PH12016500331A1 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
MX349096B (es) | Anticuerpos anti-pd-l1 y sus usos. | |
MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
NZ618062A (en) | Hsp90 combination therapy | |
WO2015035250A3 (en) | Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome | |
MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
MX2013006758A (es) | Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. | |
MX2012007898A (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
MX2021003826A (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies | |
SG10201901391RA (en) | Induction of il-12 using immunotherapy | |
BR112015028252A2 (pt) | método de tratamento de câncer de pulmão por vacinação com lipopeptídeo muc-1 | |
NZ704554A (en) | Combination therapy of a smac mimetic and gm-csf | |
WO2012019125A3 (en) | Biomarkers for prostate cancer and methods for their detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |